Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 13/20 | 0.73 |
| ▸ | BCHE | P06276 | 10/20 | 0.73 |
| ▸ | LMNA | P02545 | 2/20 | 0.73 |
| ▸ | MEN1 | O00255 | 1/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.71 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.71 |
| ▸ | FAAH | O00519 | 1/20 | 0.59 |
| ▸ | MARK4 | Q96L34 | 1/20 | 0.52 |
| ▸ | MAOB | P27338 | 3/20 | 0.49 |
| ▸ | MAOA | P21397 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29388689 | 0.90 | ACHE (0.78) | ACHEBCHELMNAMEN1KMT2A | |
| SCHEMBL12043609 | 0.87 | ACHE (0.70) | ACHEBCHELMNAMEN1KMT2A | |
| Demecarium SCHEMBL31649032 | 0.86 | ACHE (0.69) | ACHEBCHELMNAMEN1KMT2A | |
| Demecarium SCHEMBL61421 | 0.86 | ACHE (0.69) | ACHEBCHELMNAMEN1KMT2A | |
| Demecarium SCHEMBL34283 | 0.85 | ACHE (0.70) | ACHEBCHELMNAMEN1KMT2A | |
| Demecarium SCHEMBL29425243 | 0.85 | ACHE (0.70) | ACHEBCHELMNAMEN1KMT2A | |
| Neostigmine SCHEMBL8026154 | 0.84 | ACHE (1.00) | ACHEBCHELMNAMEN1KMT2A | |
| Neostigmine SCHEMBL29603805 | 0.84 | ACHE (1.00) | ACHEBCHELMNAMEN1KMT2A | |
| Neostigmine SCHEMBL34419 | 0.84 | ACHE (1.00) | ACHEBCHELMNAMEN1KMT2A | |
| Neostigmine SCHEMBL16228482 | 0.83 | ACHE (0.97) | ACHEBCHELMNAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012170599-A1 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | BRAINCELLS, INC. (US) | 2012-12-13 | — | — | WO | disclosed |
| US-20110319386-A1 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | BRAINCELLS INC. (US) | 2011-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319386-A1 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | CHRNB2, CHAT, CHRNB4 | ACHE 18/4885BCHE 42/4885LMNA 3625/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.